This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| SCD1 | |
|---|---|
| Name | Stearoyl-CoA desaturase-1 |
| Caption | Crystal structure model |
| Location | Endoplasmic reticulum |
| Enzyme class | EC 1.14.19.1 |
SCD1 SCD1 is a membrane-bound enzyme that introduces a cis double bond into saturated fatty acyl-CoAs, converting stearoyl-CoA to oleoyl-CoA and palmitoyl-CoA to palmitoleoyl-CoA. Important in lipid metabolism, SCD1 activity influences membrane composition, lipid signaling, and energy homeostasis across mammalian tissues including liver, adipose, and brain. Research on SCD1 intersects with studies from institutions like Harvard University, National Institutes of Health, University of Cambridge, and pharmaceutical efforts by Pfizer, Novartis, and Roche.
SCD1 is a delta-9 desaturase first characterized in studies referencing work at Rockefeller University and biochemical analyses influenced by techniques from laboratories at Massachusetts Institute of Technology and Stanford University. Its discovery built on earlier enzyme research by groups connected to Max Planck Society and historical lipid studies that involved scientists affiliated with University of Oxford and Columbia University. SCD1 research appears in journals associated with Nature Publishing Group, Cell Press, and Proceedings of the National Academy of Sciences.
The gene encoding SCD1 is located on human chromosome 10, mapped using methods developed at European Molecular Biology Laboratory and databanks like those maintained by National Center for Biotechnology Information. The SCD1 protein is an integral endoplasmic reticulum membrane protein with multiple transmembrane helices characterized using cryo-electron microscopy techniques advanced at EMBL-EBI and structural biology efforts at Cold Spring Harbor Laboratory. Conserved histidine motifs coordinating di-iron centers mirror descriptions from metalloprotein studies at Lawrence Berkeley National Laboratory and structural paradigms reported by researchers at California Institute of Technology.
SCD1 catalyzes a dehydrogenation/desaturation reaction using molecular oxygen and cytochrome b5 electron transfer, a mechanism elucidated by comparative studies from research groups at University of California, Berkeley and Johns Hopkins University. The catalytic cycle involves di-iron centers and histidine-rich motifs; mechanistic parallels were discussed in work from Max Planck Institute for Biophysical Chemistry and peroxidase/desaturase research conducted at Scripps Research. Biochemical assays frequently reference methods standardized by investigators at Yale University and University of Chicago.
SCD1 expression is transcriptionally regulated by sterol regulatory element-binding proteins linked to findings at Howard Hughes Medical Institute labs and by liver X receptors studied by teams at University of Texas Southwestern Medical Center. Hormonal regulation involves insulin and leptin signaling pathways described in work from University of Pennsylvania and Rockefeller University. Nutritional modulation of SCD1 was documented in large studies involving cohorts coordinated with World Health Organization protocols and metabolic research from Karolinska Institute.
SCD1-generated monounsaturated fatty acids support membrane fluidity and lipid droplet formation, themes explored in cell-biology work at University of California, San Francisco and Imperial College London. Roles in adipogenesis, thermogenesis, and hepatic lipid storage were characterized in animal models developed at National Institute of Diabetes and Digestive and Kidney Diseases and comparative physiology studies at Smithsonian Institution museums. SCD1 influences insulin sensitivity and whole-body energy balance, subjects of collaborations including Dana-Farber Cancer Institute and metabolic centers at Mayo Clinic.
Altered SCD1 activity is implicated in metabolic syndromes, nonalcoholic fatty liver disease noted in epidemiological studies coordinated with Centers for Disease Control and Prevention and obesity research at University of Cambridge. Elevated SCD1 expression correlates with tumorigenesis in contexts investigated by oncology groups at Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and Dana-Farber Cancer Institute. Associations with cardiovascular disease, atherosclerosis, and inflammatory disorders have been examined in consortia including American Heart Association and clinical research networks at Cleveland Clinic.
SCD1 is a candidate therapeutic target for obesity, diabetes, and cancer; small-molecule inhibitors and antisense oligonucleotides have been developed in programs at Pfizer, Novartis, and biotechnology firms incubated at Cambridge Innovation Center. Clinical trials overseen by regulatory agencies such as Food and Drug Administration and coordinated through academic medical centers including Johns Hopkins Hospital and Mayo Clinic examine safety and metabolic effects. Biomarker studies incorporating metabolomics platforms at Broad Institute and precision medicine initiatives at Genentech evaluate SCD1-related lipid signatures for stratified therapies.
Category:Human proteins